A bounded review of two sponsor-funded randomized Phase 2 trials: one in obesity and one in metabolic dysfunction-associated steatohepatitis with fibrosis.12
Bottom line from this bounded source set
The reviewed obesity trial reported greater weight reduction than placebo, and the reviewed liver-disease trial reported more participants with improvement in steatohepatitis without worsening fibrosis. Both are mid-stage studies with substantial remaining uncertainty.12
Reviewed study record
Phase 2 obesity trial
Design
A randomized, double-blind, placebo-controlled dose-finding Phase 2 trial assessed body-weight change over 46 weeks.1
Population
The trial treated 386 adults with overweight or obesity without diabetes across 43 centers in 12 countries.1
Outcomes reported
Reported mean body-weight change ranged from -6.2% to -14.9% across planned survodutide groups and was -2.8% with placebo. About 60% completed the treatment period, and gastrointestinal events were more frequent with survodutide.1
Limitations
The sponsor-funded trial was Phase 2, had substantial treatment-period attrition, and Crossref registers a publisher erratum with two upstream dates for the same notice. Crossref metadata alone does not describe the corrected wording.1
Reviewed study record
Phase 2 MASH and fibrosis trial
Design
A randomized, placebo-controlled Phase 2 trial assessed histologic improvement in steatohepatitis without worsening fibrosis over 48 weeks.2
Population
The trial treated 293 adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and fibrosis stages F1 through F3.2
Outcomes reported
Improvement in steatohepatitis without worsening fibrosis was reported in 43% to 62% across survodutide groups and 14% with placebo. Improvement in fibrosis by at least one stage was reported in 34% to 36% and 22%, respectively.2
Limitations
The sponsor-funded, 48-week Phase 2 trial was not designed to establish long-term liver-related clinical outcomes or uncommon harms, and the fibrosis result was a secondary endpoint.2
Publication update registered by CrossrefErratum ↗ · publisher metadata · December 17, 2025 and February 1, 2026. Crossref metadata identifies the notice but does not by itself explain what wording changed.
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2401755. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗